Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125520952 | 12552095 | 2 | F | 20160628 | 20160713 | 20160713 | EXP | US-CIPLA LTD.-2016US09520 | CIPLA | SAIF MW, MCGEE PJ. HEMOLYTIC-UREMIC SYNDROME ASSOCIATED WITH GEMCITABINE: A CASE REPORT AND REVIEW OF LITERATURE. JOURNAL OF THE PANCREAS. 2005;6 (4):369 TO 374 | 0.00 | Y | 0.00000 | 20160713 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125520952 | 12552095 | 1 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 1000 MG/M2, WEEKLY EVERY THREE OF FOUR WEEKS | U | U | 0 | 1000 | MG/M**2 | ||||||
| 125520952 | 12552095 | 2 | PS | SERTRALINE | SERTRALINE HYDROCHLORIDE | 1 | Unknown | UNK | U | U | 77397 | ||||||||
| 125520952 | 12552095 | 3 | SS | SIMVASTATIN. | SIMVASTATIN | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 125520952 | 12552095 | 4 | SS | ATENOLOL. | ATENOLOL | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 125520952 | 12552095 | 5 | SS | ASPIRIN. | ASPIRIN | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 125520952 | 12552095 | 6 | C | Megestrol | MEGESTROL | 1 | Unknown | UNK, AS NEEDED | U | U | 0 | ||||||||
| 125520952 | 12552095 | 7 | C | PROCHLORPERAZINE. | PROCHLORPERAZINE | 1 | Unknown | UNK, AS NEEDED | U | U | 0 | ||||||||
| 125520952 | 12552095 | 8 | C | Erythropoetin | ERYTHROPOIETIN | 1 | Subcutaneous | 40000 UT, WEEKLY | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125520952 | 12552095 | 1 | Pancreatic carcinoma |
| 125520952 | 12552095 | 3 | Hypertension |
| 125520952 | 12552095 | 4 | Hypertension |
| 125520952 | 12552095 | 5 | Hypertension |
| 125520952 | 12552095 | 6 | Supportive care |
| 125520952 | 12552095 | 7 | Supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125520952 | 12552095 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125520952 | 12552095 | Bone marrow toxicity | |
| 125520952 | 12552095 | Cachexia | |
| 125520952 | 12552095 | Diarrhoea | |
| 125520952 | 12552095 | Thrombotic microangiopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |